Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug.

[1]  S. Baboota,et al.  Intranasal administration of nanostructured lipid carriers containing CNS acting drug: pharmacodynamic studies and estimation in blood and brain. , 2012, Journal of psychiatric research.

[2]  V. Sankar,et al.  Comparative studies of lamivudine-zidovudine nanoparticles for the selective uptake by macrophages. , 2012, Current drug delivery.

[3]  P. Fox,et al.  High Dimensional Endophenotype Ranking in the Search for Major Depression Risk Genes , 2012, Biological Psychiatry.

[4]  S. Baboota,et al.  Nanostructured Lipid Carrier Containing CNS Acting Drug: Formulation, Optimization and Evaluation , 2011 .

[5]  Javed Ali,et al.  Strategy for effective brain drug delivery. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  R. Gabathuler,et al.  Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases , 2010, Neurobiology of Disease.

[7]  J. Pardeike,et al.  Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. , 2009, International journal of pharmaceutics.

[8]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[9]  A. Babbar,et al.  Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. , 2008, International journal of pharmaceutics.

[10]  M. Dobrovolskaia,et al.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. , 2008, Molecular pharmaceutics.

[11]  R. Thorne,et al.  Delivery of interferon-β to the monkey nervous system following intranasal administration , 2008, Neuroscience.

[12]  R. Müller,et al.  Lipid Nanoparticles with a Solid Matrix (SLN®, NLC®, LDC®) for Oral Drug Delivery , 2008, Drug development and industrial pharmacy.

[13]  R. Pandey,et al.  Oral solid lipid nanoparticle-based antitubercular chemotherapy. , 2005, Tuberculosis.

[14]  Gary M Pollack,et al.  Nasal drug administration: potential for targeted central nervous system delivery. , 2005, Journal of pharmaceutical sciences.

[15]  R. G. Thorne,et al.  Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration , 2004, Neuroscience.

[16]  C. Kilts.  Potential new drug delivery systems for antidepressants: an overview. , 2003, The Journal of clinical psychiatry.

[17]  T. Gillespie,et al.  Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[18]  A. Misra,et al.  Drug delivery to the central nervous system: a review. , 2003, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[19]  F. Balis,et al.  Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Temozolomide in Non-human Primates , 2003, Journal of Neuro-Oncology.

[20]  M. Wuest,et al.  Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. , 2002, Journal of medicinal chemistry.

[21]  L. Illum.  Transport of drugs from the nasal cavity to the central nervous system. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  S. Ell,et al.  Nasal pH measurement: a reliable and repeatable parameter. , 1999, Clinical otolaryngology and allied sciences.

[23]  A. Perkins,et al.  Evaluation of the clearance characteristics of bioadhesive systems in humans. , 1999, International journal of pharmaceutics.

[24]  I. Wilding,et al.  Gamma scintigraphy : an in vivo technique for assessing the equivalence of inhaled products , 1998 .

[25]  A. Mitra,et al.  Effects of formulation variables on nasal epithelial cell integrity: Biochemical evaluations , 1995 .

[26]  Y. Takatsuka,et al.  Absorption of drugs from the nasal mucosa of rat , 1981 .

[27]  W. Eckelman,et al.  Instant 99mTc-DTPA. , 1970, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  P. Devarajan,et al.  Buparvaquone loaded solid lipid nanoparticles for targeted delivery in theleriosis , 2014, Journal of pharmacy & bioallied sciences.

[29]  W. Frey,et al.  Delivery of Neurotrophic Factors to the Central Nervous System , 2001, Clinical pharmacokinetics.